MedTrace Logo

Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

NCT00290147 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-06-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.

Conditions

  • Dengue

Interventions

BIOLOGICAL

D1ME100 (dengue-1 premembrane/envelope DNA vaccine)

IM injection delivered by Biojector

Sponsors & Collaborators

  • United States Army Medical Materiel Development Activity

    collaborator FED

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Charmagne Beckett, MD · Naval Medical Research Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2006-12-31
Completion
2009-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290147 on ClinicalTrials.gov